我要投票 诺迪康在中草药行业中的票数:951
· 外 推 电 报 ·
2025-09-21 21:20:04 星期日

【诺迪康是哪个国家的品牌?】

诺迪康是什么牌子?「诺迪康」是 西藏诺迪康药业股份有限公司 旗下著名品牌。该品牌发源于西藏,由创始人陈达彬在1999-07-14期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力诺迪康品牌出海!将品牌入驻外推网,定制诺迪康品牌推广信息,可以显著提高诺迪康产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

西藏诺迪康药业股份有限公司是西藏雪域高原上诞生的第一家高新技术制药上市企业,于1999年7月14日创立,1999年7月21日在上海证券交易所上网交易,股票名称:西藏药业,股票代码:600211。

在各级领导的关心和支持下,公司已经发展成为一家拥有员工4000余人,总资产8.2亿元的现代化制药企业。公司累计上缴税金2亿余元,发放员工工资、福利2.2亿余元;公司主要产品诺迪康胶囊年销售额逾亿元,公司生物一类新药重组人脑利钠肽也已经上市销售。

公司拥有西藏诺迪康医药有限公司、成都诺迪康生物制药有限公司、四川诺迪康威光制药有限公司、西藏康达药业有限公司、西藏诺迪康藏药材开发有限公司、四川本草堂药业有限公司等下属子公司。

公司秉承“科学成就健康,健康成就未来”的理念,以科技兴业。在为藏药现代化不遗余力的同时,公司注巨资于生物制品和传统药品的研发,并构建了林芝种植基地和四个生产基地及覆盖全国的营销网络。产品涵盖生物制品、藏药和中药、化学药的产品系列,奠定了西藏药业持续发展的基础,其中具有自主知识产权的生物制品一类新药新活素,代表着目前国际急性心衰急救治疗药物的最高水平,填补了该领域的国内空白。

公司上市以来连续被西藏自治区认定为高新技术企业、西藏自治区农牧业龙头企业,2001年被国家科学技术部认定为国家火炬计划重点高新技术企业。2008年公司被科技部认定为创新型试点企业。公司图形商标(祥云图)经国家工商总局认定为中国驰名商标,公司产品诺迪康胶囊和十味蒂达胶囊被评为国家中药保护品种,同时,还被国家保密局、科学技术部评为秘密级国家秘密技术。

经过多年来的不懈努力,公司已成为拥有一个国家级企业技术中心、四个符合GMP规范的药品生产基地、一个符合GAP藏药材种植基地及覆盖全国的营销网络,集藏药产品、植物药产品、化学药产品、生物制品研发、生产和销售一体的现代化企业。

英文翻译:Tibet nordikang Pharmaceutical Co., Ltd. is the first high-tech pharmaceutical listed enterprise born on the snow capped plateau of Tibet. It was founded on July 14, 1999 and traded on the Internet at Shanghai Stock Exchange on July 21, 1999. Its stock name is Tibet pharmaceutical, and its stock code is 600211. With the concern and support of leaders at all levels, the company has developed into a modern pharmaceutical enterprise with more than 4000 employees and total assets of 820 million yuan. The company has paid taxes of more than 200 million yuan and paid employees salaries and welfare of more than 220 million yuan; the annual sales volume of the company's main product, nordicon capsule, is more than 100 million yuan, and the company's new biological class I recombinant human brain natriuretic peptide has also been listed for sale. The company has subsidiaries including Tibet nordikang Pharmaceutical Co., Ltd., Chengdu nordikang biopharmaceutical Co., Ltd., Sichuan nordikang Weiguang Pharmaceutical Co., Ltd., Tibet Kangda Pharmaceutical Co., Ltd., Tibet nordikang Tibetan Medicine Development Co., Ltd., Sichuan bencaotang Pharmaceutical Co., Ltd. The company adheres to the concept of "science makes health, health makes future", and prospers with science and technology. While sparing no effort for the modernization of Tibetan medicine, the company has invested heavily in the research and development of biological products and traditional drugs, and has built the Linzhi planting base, four production bases and a nationwide marketing network. The products range from biological products, Tibetan medicine, traditional Chinese medicine and chemical medicine, laying the foundation for the sustainable development of Tibetan pharmaceutical industry, among which the biological products with independent intellectual property rights represent the highest level of international emergency treatment drugs for acute heart failure, and fill the domestic gap in this field. Since its listing, the company has been successively recognized as a high-tech enterprise in Tibet Autonomous Region, a leading enterprise in agriculture and animal husbandry in Tibet Autonomous Region, and a key high-tech enterprise in the national torch plan by the Ministry of science and technology of the people's Republic of China in 2001. In 2008, the company was recognized as an innovative pilot enterprise by the Ministry of science and technology. The company's graphic trademark (xiangyuntu) has been recognized as a well-known trademark in China by the State Administration of industry and commerce. The company's products, nordikang capsule and Shiweidida capsule, have been rated as the national traditional Chinese medicine protected varieties. Meanwhile, they have also been rated as the secret level national secret technology by the State Security Bureau and the Ministry of science and technology. After years of unremitting efforts, the company has become a modern enterprise with a national enterprise technology center, four GMP compliant pharmaceutical production bases, a gap compliant Tibetan medicine planting base and a nationwide marketing network, which integrates the research and development, production and sales of Tibetan medicine products, botanical medicine products, chemical medicine products and biological products.

本文链接: https://www.waitui.com/brand/0b45a7af1.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

山西汾酒:股东华创鑫睿计划减持不超1.33%公司股份

36氪获悉,山西汾酒发布公告,根据联和基金相关合作协议,其面临基金到期退出安排,需要减持其间接持有的全部公司股份,因此持股5%以上股东华创鑫睿本次拟通过大宗交易方式减持不超过1620.06万股(含本数),计划减持比例不超过1.33%;自本次减持计划公开披露之日起15个交易日后的3个月内(含3个月期满当日)实施。

2小时前

中信证券:三方面的技术趋势将推动刻蚀设备的用量和重要性提升

36氪获悉,中信证券预计,至少以下三方面的技术趋势将推动刻蚀设备的用量和重要性提升:1.光刻多重图案化路线的采用;2.三维堆叠存储和近存计算需求;3.底层晶体管结构升级。长期看,半导体设备国产化方向明确,短期来看,下游扩产有望驱动行业进入新一轮增长期。建议关注国内刻蚀设备厂商以及相关配套设备、零部件企业机会。

2小时前

中信证券:右侧趋势品种继续聚焦资源、消费电子、创新药和游戏

36氪获悉,中信证券研报表示,目前整体的行业选择框架依然是围绕资源+新质生产力+出海。资源股在供给受限以及全球地缘动荡的预期推动下,从周期属性转向偏红利属性会带来估值体系重构,博弈美联储降息的资金退潮带来的波动可以忽略。更大的中期线索还是中国制造业龙头的全球化,将份额优势转化为定价权和利润率提升,带来超越本国经济基本面的市值增长,从而逐步打破行情与基本面背离且全靠流动性驱动的错误认知。配置结构上,保持定力,右侧趋势品种继续聚焦资源、消费电子、创新药和游戏;左侧配置关注化工和军工;产业趋势层面,近期重点关注AI从云侧逻辑开始向端侧逻辑扩散。

2小时前

环球印务:股东香港原石拟减持不超1%公司股份

36氪获悉,环球印务发布公告,持股10.98%的股份的股东香港原石国际有限公司(简称“香港原石”)计划以集中竞价交易合计减持不超过320.04万股公司股份,占公司总股本比例的1%。

2小时前

冠中生态:筹划控制权变更事项,股票停牌

36氪获悉,冠中生态发布公告,公司控股股东青岛冠中投资集团有限公司及实际控制人李春林和许剑平正在筹划公司控制权变更相关事宜,可能导致公司控股股东及实际控制人发生变更。经申请,公司股票及可转换公司债券自2025年9月22日起停牌,预计停牌时间不超过2个交易日。停牌期间,公司可转换公司债券“冠中转债”将暂停转股。

2小时前

本页详细列出关于诺迪康的品牌信息,含品牌所属公司介绍,诺迪康所处行业的品牌地位及优势。
咨询